Yale Psychiatry Names New Research Leaders at Connecticut Mental Health Center
Marina Picciotto, PhD, Deputy Chair for Basic Science and Charles B.G. Murphy Professor of Psychiatry, of Neuroscience, of Pharmacology and in the Child Study Center, has been named Director of the Ribicoff Labs and of the Division of Molecular Psychiatry. Christopher Pittenger, MD, PhD, Professor of Psychiatry, Assistant Chair for Translational Research, and Director of the Yale OCD Research Clinic, has been named Director of the Clinical Neuroscience Research Unit (CNRU) and of the Neuroscience Research Training Program (NRTP).
Potenza Named Director of Division on Addictions Research at Yale
Marc Potenza, MD, PhD (Yale College ’87, MD ’93, PhD ’94, Psychiatry Residency ‘98), Professor of Psychiatry, of Neuroscience, and in the Child Study Center, has been named Director of the Division on Addictions Research in the Yale Department of Psychiatry.
Fourth Annual Anesthesiology Department Celebration of Research Will Be Sept. 20-21
Renowned neuro-anesthesiologist and researcher George Mashour, MD PhD, the Bert N. Lau Professor of Anesthesiology Research and Associate Dean at University of Michigan Medical School, will be the keynote speaker.
Doris Duke Fund to Retain Clinical Scientists Now Accepting Applications
This program provides research funds to a select number of junior physician-scientists who are strongly committed to careers in clinical research, are engaged in funded research, and have a compelling need for the award in order to maintain research productivity in the face of extraordinary caregiving needs.
Genome screen uncovers new targets for cancer immunotherapy
A new genome-wide screen of 20,000 human genes in T cells have turned up several new candidates to unleash the immune system’s ability to attack a variety of tumor types, Yale Cancer Center researchers report Aug. 22 in the journal Cell.
Yale's Review of Advances in Oncology on June 14: Highlights from the ASCO® Annual Meeting 2019
Due to budgetary and time constraints, many oncologists and researchers are unable to attend the American Society of Clinical Oncology (ASCO®) Annual Meeting and would benefit from this update. The goal of Yale’s Review of Advances in Oncology is to provide hematologists, medical oncologists, and oncology nurses with Yale’s perspective on current data and information presented at the ASCO® Annual Meeting 2019.
New Stem-cell Cultivation Procedure Boosts Hope for Cures
When the Taylor lab in Yale’s Division of Reproductive Sciences extracted stem cells from human endometrial tissue—more commonly known as the uterine lining—the researchers were proud of their accomplishment. They didn’t think the find was extraordinary, and they certainly didn’t imagine that it might lead to treatments for a neurodegenerative condition. They were wrong—and happily so.
A Joint YNHHS/YSM Medical Staff and Faculty Engagement Survey
This year, Yale New Haven Health System (YNHHS) and Yale School of Medicine (YSM) are collaborating on a joint medical staff and faculty engagement survey, which will be administered from May 13 to June 3, 2019 by Press Ganey Associates, Inc.
Yale New Haven Hospital Announces Plans to Build State-of-the-art Neurosciences Center on Its Saint Raphael Campus
The School of Medicine will be a major participant in the planning and operation of the $838 million facility, which will focus on innovation in the neurosciences and include two new patient facilities. Projected opening is in 2024.
Endocrine diseases ‘emerging epidemic’ after immune checkpoint inhibitor therapies
Recently approved immune checkpoint inhibitor therapies are now increasingly used for a variety of cancers and other conditions, yet clinicians are only beginning to confront a range of endocrinopathies triggered by such treatments, including thyroid disease, pituitary disorders and insulin-dependent diabetes, according to a speaker here.Source: Healio
For Teens Living with Cancer, Keeping Life as 'Normal' as Possible
Yale New Haven Children's Hospital has opened the Lauren Telesz/Smilow Teen Center, to fill an important gap between pediatric and adult cancer care. The center dovetails with a larger goal to help improve survival rates for adolescents and young adults with cancer.Source: Yale Medicine
Protein-slaying Drugs Could Be the Next Blockbuster Therapies
A drug strategy called targeted protein degradation; and pursued by Craig Crews, PhD, Lewis B. Cullman Professor of Molecular, Cellular, and Developmental Biology, and professor of chemistry; capitalizes on the cell’s natural system for clearing unwanted or damaged proteins, and is in line to be used in promising clinical trials.Source: Nature
Protection from Zika Virus May Lie in a Protein Derived from Mosquitoes
By targeting a protein found in the saliva of mosquitoes that transmit Zika virus, Yale investigators reduced Zika infection in mice. The finding demonstrates how researchers might develop a vaccine against Zika and similar mosquito-borne viruses, the study authors said.